Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:endDate |
2022
|
| gptkbp:focusesOn |
gptkb:Alzheimer's_disease
|
| gptkbp:fullName |
gptkb:Clarity_AD
|
| https://www.w3.org/2000/01/rdf-schema#label |
CLARITY
|
| gptkbp:location |
international
|
| gptkbp:participants |
1795
|
| gptkbp:period |
Phase 3
|
| gptkbp:recognizedBy |
gptkb:NCT03887455
|
| gptkbp:result |
change in CDR-SB score
|
| gptkbp:sponsor |
gptkb:Biogen
gptkb:Eisai |
| gptkbp:startYear |
2019
|
| gptkbp:studies |
gptkb:lecanemab
|
| gptkbp:bfsParent |
gptkb:Karl_Deisseroth
|
| gptkbp:bfsLayer |
5
|